XML 102 R83.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment and Geographic Information - Company's Segment Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Revenue $ 739,016 $ 563,948 $ 449,538
Net loss (436,373) (479,449) (654,588)
Reportable Segment      
Segment Reporting Information [Line Items]      
Revenue 739,016 563,948 449,538
Cost of precision oncology testing 254,551 200,202 141,691
Cost of development services and other 24,886 18,863 8,126
Research and development expense 295,866 329,826 341,650
Sales and marketing expense 328,064 270,132 273,961
General and administrative expense 133,352 129,247 121,023
Other segment items 138,670 95,127 217,675
Net loss $ (436,373) $ (479,449) $ (654,588)